Nystatin Cream USP, 100,000 units per gram

Manufacturer
NuCare Pharmaceuticals,Inc.
Effective date
2025-02-10
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
3
Source
full-release
Hydrated at
2026-05-31 21:25:34

Label at a glance#

ProductNystatin
Active ingredientNYSTATIN
Label structure11 sections

Indications and uses

Nystatin cream is indicated in the treatment of cutaneous or mucocutaneous mycotic infections caused by Candida albicans and other susceptible Candida species. This cream is not indicated for systemic, oral, intravaginal or ophthalmic use.

Dosage and administration

Apply liberally to affected areas twice daily or as indicated until healing is complete.

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

Rx only

FOR TOPICAL USE ONLY • NOT FOR OPHTHALMIC USE

DESCRIPTION

DESCRIPTION SECTION

Nystatin is a polyene antifungal antibiotic obtained from Streptomyces nursei.

Structural formula:

Chemical Structure
Chemical Structure

Nystatin cream is for dermatologic use.

Nystatin cream for topical use, contains 100,000 USP nystatin units per gram in an aqueous, perfumed cream base containing aluminum hydroxide gel, ceteareth-15, glyceryl monostearate, polyethylene glycol 400 monostearate, propylene glycol, purified water, simethicone emulsion, sorbitol solution, titanium dioxide, white petrolatum, with methylparaben and propylparaben as preservatives and, if necessary, sodium hydroxide for pH adjustment.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Pharmacokinetics

PHARMACOKINETICS SECTION

Nystatin is not absorbed from intact skin or mucous membrane.

Microbiology

MICROBIOLOGY SECTION

Nystatin is an antibiotic which is both fungistatic and fungicidal in vitro against a wide variety of yeasts and yeast-like fungi, including Candida albicans, C. parapsilosis, C. tropicalis, C. guilliermondi, C. pseudotropicalis, C. krusei, Torulopsis glabrata, Tricophyton rubrum, T. mentagrophytes. Nystatin acts by binding to sterols in the cell membrane of susceptible species resulting in a change in membrane permeability and the subsequent leakage of intracellular components. On repeated subculturing with increasing levels of nystatin, Candida albicans does not develop resistance to nystatin. Generally, resistance to nystatin does not develop during therapy. However, other species of Candida (C. tropicalis, C. guilliermondi, C. krusei, and C. stellatoides) become quite resistant on treatment with nystatin and simultaneously become cross resistant to amphotericin as well. This resistance is lost when the antibiotic is removed. Nystatin exhibits no appreciable activity against bacteria, protozoa, or viruses.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Nystatin cream is indicated in the treatment of cutaneous or mucocutaneous mycotic infections caused by Candida albicans and other susceptible Candida species.

This cream is not indicated for systemic, oral, intravaginal or ophthalmic use.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Nystatin cream is contraindicated in patients with a history of hypersensitivity to any of its components.

PRECAUTIONS

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

Nystatin cream should not be used for the treatment of systemic, oral, intravaginal or ophthalmic infections.

If irritation or sensitization develops, treatment should be discontinued and appropriate measures taken as indicated. It is recommended that KOH smears, cultures, or other diagnostic methods be used to confirm the diagnosis of cutaneous or mucocutaneous candidiasis and to rule out infection caused by other pathogens.

INFORMATION FOR THE PATIENT

INFORMATION FOR PATIENTS SECTION

Patients using this medication should receive the following information and instructions:

  1. The patient should be instructed to use this medication as directed (including the replacement of missed doses). This medication is not for any disorder other than that for which it is prescribed.
  2. Even if symptomatic relief occurs within the first few days of treatment, the patient should be advised not to interrupt or discontinue therapy until the prescribed course of treatment is completed.
  3. If symptoms of irritation develop, the patient should be advised to notify the physician promptly.

Laboratory Tests

LABORATORY TESTS SECTION

If there is a lack of therapeutic response, KOH smears, cultures, or other diagnostic methods should be repeated.

Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

No long-term animal studies have been performed to evaluate the carcinogenic potential of nystatin. No studies have been performed to determine the mutagenicity of nystatin or the effects on male or female fertility.

Pregnancy

PREGNANCY SECTION

Teratogenic Effects

TERATOGENIC EFFECTS SECTION

Category C

SPL UNCLASSIFIED SECTION

Animal reproduction studies have not been conducted with any nystatin cream. It also is not known whether this cream can cause fetal harm when used by a pregnant woman or can affect reproductive capacity. Nystatin cream should be prescribed for a pregnant woman only if the potential benefit to the mother outweighs the potential risk to the fetus.

Nursing Mothers

NURSING MOTHERS SECTION

It is not known whether nystatin is excreted in human milk. Caution should be exercised when nystatin is prescribed for a nursing woman.

Pediatric Use

PEDIATRIC USE SECTION

Safety and effectiveness have been established in the pediatric population from birth to 16 years.

(See DOSAGE AND ADMINISTRATION.)

Geriatric Use

GERIATRIC USE SECTION

Clinical studies with nystatin cream did not include sufficient numbers of subjects aged 65 years and older to determine whether they respond differently than younger subjects. Other reported clinical experience has not identified differences in responses between elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

The frequency of adverse events reported in patients using nystatin cream is less than 0.1%. The more common events that were reported include allergic reactions, burning, itching, rash, eczema, and pain on application.

(See PRECAUTIONS: General.)

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Adults and Pediatric Patients (Neonates and Older)

SPL UNCLASSIFIED SECTION

Apply liberally to affected areas twice daily or as indicated until healing is complete.

HOW SUPPLIED

HOW SUPPLIED SECTION

Nystatin Cream USP is a smooth yellow to light green cream with a characteristic perfume odor.

Nystatin Cream USP is supplied in 15 g (NDC 68071-2556-5) tubes providing 100,000 USP Nystatin Units per gram.

STORAGE AND HANDLING SECTION

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Avoid freezing.

SPL UNCLASSIFIED SECTION

Mfd. by: Taro Pharmaceutical Industries Ltd.
Haifa Bay, Israel 2624761

Dist. by: Taro Pharmaceuticals U.S.A., Inc., Hawthorne, NY 10532

Revised: October, 2019

20247-1019-1        31

PRINCIPAL DISPLAY PANEL -

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

pdppdp

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
543546nystatin 100,000 UNT/GM Topical CreamPSN3
543546nystatin 100000 UNT/ML Topical CreamSCD3
543546nystatin 100,000 UNT/GM Topical CreamSY3

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
NYSTATIN Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
e29fe634-dc25-094c-c77f-5d09c3eceb3eProduct name520260107
e57b6340-9387-3f9a-7307-511c81791375Product name320221214
544f8e8d-6389-eeeb-9586-aa447c08dcc7Product name520210614
1629e00f-54fb-4a43-8306-b58442b23902Product name920200430
854ec07b-1cd7-a5db-235a-7aa24d3cf97aProduct name320180628
19b9f4c1-15e9-edcc-4c16-f01ecfb5c549Product name120140508

FDA-Initiated Inactive NDC Indexing#

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
68071-2556-5Nystatin15 g in 1 TUBECREAM153
68071-2556-5Nystatin1 in 1 CARTONCREAM13

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
68071-2556NYSTATIN CREAM [NUCARE PHARMACEUTICALS,INC.]3Current NDC, Legacy NDC, 2 package rows20250212_cf6b7c68-7769-1808-e053-2995a90aa426.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
51672-1289-1GM - Gram51672-128938067616-cd05-468d-a844-b2ec0513e43f12012-07-24
51672-1289-2GM - Gram51672-12894f7b2183-b586-49ab-9a71-4e40d5479cb912012-07-24

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 12 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
68071-255668071-2556-5
51672-1289

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 12 matching rows.

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A064022-001NYSTATINNYSTATIN100,000 UNITS/GMCREAM / TOPICALATRS1993-01-29

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
A064022-001AT

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A064022-001NYSTATIN100,000 UNITS/GMCREAM / TOPICALATRS1993-01-2984e616aacf4f…
2026-08-18 06:07:402026-07A064022-001NYSTATIN100,000 UNITS/GMCREAM / TOPICALATRS1993-01-29caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A064022-001NYSTATIN100,000 UNITS/GMCREAM / TOPICALATRS1993-01-29011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A064022-001NYSTATIN100,000 UNITS/GMCREAM / TOPICALATRS1993-01-2931067a03dcf5…
2025-08-23 18:47 UTC2025-08A064022-001NYSTATIN100,000 UNITS/GMCREAM / TOPICALATRS1993-01-296a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A064022-001NYSTATIN100,000 UNITS/GMCREAM / TOPICALATRS1993-01-29fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A064022-001NYSTATIN100,000 UNITS/GMCREAM / TOPICALATRS1993-01-29b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A064022-001NYSTATIN100,000 UNITS/GMCREAM / TOPICALATRS1993-01-2903ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A064022-001NYSTATIN100,000 UNITS/GMCREAM / TOPICALATRS1993-01-292680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A064022-001NYSTATIN100,000 UNITS/GMCREAM / TOPICALATRS1993-01-295bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A064022-001NYSTATIN100,000 UNITS/GMCREAM / TOPICALATRS1993-01-29d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A064022-001NYSTATIN100,000 UNITS/GMCREAM / TOPICALATRS1993-01-29d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A064022-001NYSTATIN100,000 UNITS/GMCREAM / TOPICALATRS1993-01-2979d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A064022-001NYSTATIN100,000 UNITS/GMCREAM / TOPICALATRS1993-01-29301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A064022-001NYSTATIN100,000 UNITS/GMCREAM / TOPICALATRS1993-01-291e350fbaab3a…
2024-05-31 18:47 UTC2024-05A064022-001NYSTATIN100,000 UNITS/GMCREAM / TOPICALATRS1993-01-298072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A064022-001NYSTATIN100,000 UNITS/GMCREAM / TOPICALATRS1993-01-295c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A064022-001NYSTATIN100,000 UNITS/GMCREAM / TOPICALATRS1993-01-295d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A064022-001NYSTATIN100,000 UNITS/GMCREAM / TOPICALATRS1993-01-294b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A064022-001NYSTATIN100,000 UNITS/GMCREAM / TOPICALATRS1993-01-2974a2ff9319b5…
2022-03-09 01:35 UTC2022-03A064022-001NYSTATIN100,000 UNITS/GMCREAM / TOPICALATRS1993-01-29bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A064022-001NYSTATIN100,000 UNITS/GMCREAM / TOPICALATRS1993-01-29782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A064022-001NYSTATIN100,000 UNITS/GMCREAM / TOPICALATRS1993-01-2987673890dc5c…
2021-03-12 10:30 UTC2021-03A064022-001NYSTATIN100,000 UNITS/GMCREAM / TOPICALATRS1993-01-295aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A064022-001NYSTATIN100,000 UNITS/GMCREAM / TOPICALATRS1993-01-298869cabd3fbd…
2020-11-12 02:37 UTC2020-11A064022-001NYSTATIN100,000 UNITS/GMCREAM / TOPICALATRS1993-01-29c0c555d07b60…
2019-12-14 00:12 UTC2019-12A064022-001NYSTATIN100,000 UNITS/GMCREAM / TOPICALATRS1993-01-293f01610625f2…
2019-09-15 20:21 UTC2019-09A064022-001NYSTATIN100,000 UNITS/GMCREAM / TOPICALATRS1993-01-29b00525d2431f…
2019-07-19 19:46 UTC2019-07A064022-001NYSTATIN100,000 UNITS/GMCREAM / TOPICALATRS1993-01-29ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A064022-001NYSTATIN100,000 UNITS/GMCREAM / TOPICALATRS1993-01-296a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A064022-001NYSTATIN100,000 UNITS/GMCREAM / TOPICALATRS1993-01-291c564ffb4f44…
2023-12-20 04:57 UTC2023-12A064022-001NYSTATIN100,000 UNITS/GMCREAM / TOPICALATRS1993-01-29ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A064022-001NYSTATIN100,000 UNITS/GMCREAM / TOPICALATRS1993-01-29a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A064022-001NYSTATIN100,000 UNITS/GMCREAM / TOPICALATRS1993-01-299b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A064022-001NYSTATIN100,000 UNITS/GMCREAM / TOPICALATRS1993-01-29a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A064022-001NYSTATIN100,000 UNITS/GMCREAM / TOPICALATRS1993-01-293f0d92c62455…
2023-05-13 08:27 UTC2023-05A064022-001NYSTATIN100,000 UNITS/GMCREAM / TOPICALATRS1993-01-29053a50430f4f…
2023-01-26 05:58 UTC2023-01A064022-001NYSTATIN100,000 UNITS/GMCREAM / TOPICALATRS1993-01-293bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A064022-001NYSTATIN100,000 UNITS/GMCREAM / TOPICALATRS1993-01-293a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A064022-001NYSTATIN100,000 UNITS/GMCREAM / TOPICALATRS1993-01-29f41ea6bd6efb…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-09-14 22:38:342026-08A064022-001AT184e616aacf4f…
2026-08-18 06:07:402026-07A064022-001AT1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A064022-001AT1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A064022-001AT131067a03dcf5…
2025-08-23 18:47 UTC2025-08A064022-001AT16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A064022-001AT1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A064022-001AT1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A064022-001AT103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A064022-001AT12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A064022-001AT15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A064022-001AT1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A064022-001AT1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A064022-001AT179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A064022-001AT1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A064022-001AT11e350fbaab3a…
2024-05-31 18:47 UTC2024-05A064022-001AT18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A064022-001AT15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A064022-001AT15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A064022-001AT14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A064022-001AT174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A064022-001AT1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A064022-001AT1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A064022-001AT187673890dc5c…
2021-03-12 10:30 UTC2021-03A064022-001AT15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A064022-001AT18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A064022-001AT1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A064022-001AT13f01610625f2…
2019-09-15 20:21 UTC2019-09A064022-001AT1b00525d2431f…
2019-07-19 19:46 UTC2019-07A064022-001AT1ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A064022-001AT16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A064022-001AT11c564ffb4f44…
2023-12-20 04:57 UTC2023-12A064022-001AT1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A064022-001AT1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A064022-001AT19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A064022-001AT1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A064022-001AT13f0d92c62455…
2023-05-13 08:27 UTC2023-05A064022-001AT1053a50430f4f…
2023-01-26 05:58 UTC2023-01A064022-001AT13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A064022-001AT13a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A064022-001AT1f41ea6bd6efb…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 2 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
NystatinNYSTATINSun Pharmaceutical Industries, Inc.4d845b3f-ca26-4c47-b424-b6d783cc10e52025-07-03Adverse reactionsExact identifier
ndc (product): 51672-1289
NystatinNYSTATINNuCare Pharmaceuticals,Inc.cf6b7c68-7769-1808-e053-2995a90aa4262025-02-10Adverse reactionsExact identifier
ndc (package): 68071-2556-5
ndc (product): 68071-2556
ndc11 (package): 68071255605
spl id: 2dcc540d-ce8e-d0a7-e063-6294a90a646c
spl set id: cf6b7c68-7769-1808-e053-2995a90aa426

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.